scholarly journals The C11orf30-LRRC32 region is associated with total serum IgE levels in asthmatic patients

2012 ◽  
Vol 129 (2) ◽  
pp. 575-578.e9 ◽  
Author(s):  
Xingnan Li ◽  
Elizabeth J. Ampleford ◽  
Timothy D. Howard ◽  
Wendy C. Moore ◽  
Huashi Li ◽  
...  
Author(s):  
Hamdia Yousif Issa ◽  
Ali A. Ramadhan ◽  
Abdulazeez S. Safo ◽  
Omar A. M. Al Habib

Background: Bronchial asthma is a disease characterized by reversible airway obstruction, airway inflammation; and hyper-responsiveness. The prevalence of asthma is high, and both its prevalence and burden have increased over the last several decades. The study of inflammatory markers has implications for the appropriate management of this disease. Inflammatory markers has implications for the appropriate management of this disease. Objective of the study is to determine the correlation between asthma severity using pulmonary function tests with sputum eosinophilia and total serum IgE levels.Methods: This case-control study was conducted from March 2017 to September 2018 in the respiratory unit of Azadi general teaching hospital. It included 42 asthmatic patients and 18 healthy subjects. They underwent pulmonary function tests and measurement of total serum IgE levels. Induced sputum was done for asthmatic patients.Results: The age of asthmatic patients ranged from 16-70 years (mean 42±19 years). The asthmatic patient’s female: male ratio was 1.8. Mild asthma was the most common severity group (N=18, 43%) followed by moderate asthma (N=14, 33%) then severe asthma (N=10, 24%). Abnormal sputum eosinophilia (≥3%) was detected in 90% of severe asthma (N=9) compared to 36% in moderate asthma (N=5) and 5.6% in mild asthma (N=1). There was significant statistical association between asthma severity and sputum eosinophilia (p=0.00004). The association between asthma severity and total serum IgE levels was highly significant (p<0.0000) with levels of total serum IgE increasing as the severity of asthma increases.Conclusions: Severe asthma is the least common severity group in this study. Both abnormal sputum eosinophilia and total serum IgE levels are associated with the severity of asthma.


Author(s):  
Renaud Louis ◽  
Charles Pilette ◽  
Olivier Michel ◽  
Alain Michils ◽  
Guy Brusselle ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Giovanna Elisiana Carpagnano ◽  
Emanuela Resta ◽  
Massimiliano Povero ◽  
Corrado Pelaia ◽  
Mariella D’Amato ◽  
...  

AbstractSevere asthma is burdened by frequent exacerbations and use of oral corticosteroids (OCS), which worsen patients’ health and increase healthcare spending. The aim of this study was to assess the clinical and economic impact of switching from omalizumab (OMA) to mepolizumab (MEP) in patients eligible for both biologics, but not optimally controlled by omalizumab. We retrospectively enrolled uncontrolled severe asthmatic patients who switched from OMA to MEP during the last two years. Information included blood eosinophil count, asthma control test (ACT), spirometry, serum IgE, fractional exhaled nitric oxide (FeNO), OCS intake, drugs, exacerbations/hospitalizations, visits and diagnostic exams. Within the perspective of Italian National Health System, a pre- and post-MEP 12-month standardized total cost per patient was calculated. 33 patients were enrolled: five males, mean age 57 years, disease onset 24 years. At OMA discontinuation, 88% were OCS-dependent with annual mean rate of 4.0 clinically significant exacerbations, 0.30 exacerbations needing emergency room visits or hospitalization; absenteeism due to disease was 10.4 days per patient. Switch to MEP improved all clinical outcomes, reducing total exacerbation rate (RR = 0.06, 95% CI 0.03–0.14), OCS-dependent patients (OR = 0.02, 95% CI 0.005–0.08), and number of lost working days (Δ = − 7.9, 95% CI − 11.2 to − 4.6). Pulmonary function improved, serum IgE, FeNO and eosinophils decreased. Mean annual costs were €12,239 for OMA and €12,639 for MEP (Δ = €400, 95% CI − 1588–2389); the increment due to drug therapy (+ €1,581) was almost offset by savings regarding all other cost items (− €1,181). Patients with severe eosinophilic asthma, not controlled by OMA, experienced comprehensive benefits by switching to MEP with only slight increases in economic costs.


Allergy ◽  
2009 ◽  
Vol 64 (9) ◽  
pp. 1327-1332 ◽  
Author(s):  
C.-M. Chen ◽  
S. Weidinger ◽  
N. Klopp ◽  
S. Sausenthaler ◽  
W. Bischof ◽  
...  

2001 ◽  
Vol 87 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Miyuki Kono ◽  
Hiroyuki Mochizuki ◽  
Hirokazu Arakawa ◽  
Masahiko Kato ◽  
Kenichi Tokuyama ◽  
...  

2011 ◽  
Vol 187 (5) ◽  
pp. 2794-2802 ◽  
Author(s):  
Justin Mostecki ◽  
Suzanne L. Cassel ◽  
Walter T. Klimecki ◽  
Debra A. Stern ◽  
Judit Knisz ◽  
...  
Keyword(s):  

2013 ◽  
Vol 65 (8) ◽  
pp. 561-568 ◽  
Author(s):  
Ming Liao ◽  
Dianchun Shi ◽  
Yao Wang ◽  
Kai Zhang ◽  
Xin Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document